Thymosin Beta-4
43-amino-acid actin-sequestering peptide (full-length thymosin beta-4)
Thymosin beta-4 is a naturally occurring 43-amino-acid peptide and a major intracellular actin-sequestering molecule. It is the full-length parent from which the research fragment commonly sold as TB-500 is derived, and it is studied for tissue repair, angiogenesis, and cell migration. It remains investigational.
Mechanism under study
Sequesters monomeric G-actin to regulate cytoskeletal dynamics and cell migration, and is studied for promoting angiogenesis and wound healing while downregulating inflammation. Investigated in models of corneal, cardiac, and dermal injury; the full 43-mer differs from the shorter actin-binding fragment marketed as TB-500.
Research-reported dosing
Research-community protocols for the full-length peptide commonly reference subcutaneous doses in the low-milligram range (often around 2-5 mg per week, sometimes divided) across multi-week cycles; formal human injectable dosing is not established. Distinct from the TB-500 fragment. Investigational; not an approved drug.
10 mg vial + 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit is approximately 0.05 mg (50 mcg).
A 2.5 mg dose ≈ 50 units (50 mcg per unit).
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Thymosin Beta-4 FAQ
What is Thymosin Beta-4?
Thymosin beta-4 is a naturally occurring 43-amino-acid peptide and a major intracellular actin-sequestering molecule. It is the full-length parent from which the research fragment commonly sold as TB-500 is derived, and it is studied for tissue repair, angiogenesis, and cell migration. It remains investigational.
What is the half-life of Thymosin Beta-4?
Reported plasma half-life on the order of hours; pharmacokinetics of the full-length 43-mer differ from those of the shorter TB-500 fragment.
What is the research-reported dosing for Thymosin Beta-4?
Research-community protocols for the full-length peptide commonly reference subcutaneous doses in the low-milligram range (often around 2-5 mg per week, sometimes divided) across multi-week cycles; formal human injectable dosing is not established. Distinct from the TB-500 fragment. Investigational; not an approved drug.
How is Thymosin Beta-4 reconstituted?
10 mg vial + 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit is approximately 0.05 mg (50 mcg).
Is Thymosin Beta-4 FDA-approved?
Thymosin Beta-4 has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.
References
Related peptides
TB-500
Synthetic actin-binding peptide fragment
A synthetic fragment related to Thymosin Beta-4, a naturally occurring actin-regulating peptide. Studied in preclinical models for cell migration, wound healing, and flexibility.
BPC-157
Synthetic pentadecapeptide
A stable synthetic peptide based on a partial sequence identified in gastric juice. It is one of the most-studied research peptides for connective-tissue and gut-lining repair in animal models.
GHK-Cu
Copper-binding tripeptide (Gly-His-Lys)
A naturally occurring copper-binding tripeptide whose plasma level declines with age. Extensively studied in skin biology for remodeling, and in topical cosmetic formulations.